Gilead Sciences Inc (NAS:GILD)
$ 64.6 -0.34 (-0.52%) Market Cap: 80.48 Bil Enterprise Value: 98.68 Bil PE Ratio: 179.39 PB Ratio: 4.61 GF Score: 74/100

Merck & Co to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead Sciences Inc - Conference Call Transcript

Mar 15, 2021 / 12:00PM GMT
Release Date Price: $63.07 (+2.45%)
Operator

Good morning. My name is Laura, and I will be your conference operator today. At this time, I would like to welcome everyone as Merck Announces HIV Collaboration with Gilead. (Operator Instructions)

I would now like to turn the call over to Peter Dannenbaum, Vice President, Investor Relations. Sir, please go ahead.

Peter Dannenbaum
Merck & Co., Inc. - VP of IR

Thank you, Laura, and good morning. Welcome to Merck's call to discuss today's announcement of collaboration with Gilead Sciences as well as our HIV program broadly. Our speakers today will be Dr. Dean Li, President of Merck Research Labs; Dr. Daria Hazuda, Head of Infectious Disease Discovery and Research; Dr. Roy Baynes, Chief Medical Officer of Merck Research Labs and Head of Clinical Development; and Frank Clyburn, our Chief Commercial Officer.

I would like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot